111536
论文已发表
注册即可获取德孚的最新动态
IF 收录期刊
- 3.4 Breast Cancer (Dove Med Press)
- 3.2 Clin Epidemiol
- 2.6 Cancer Manag Res
- 2.9 Infect Drug Resist
- 3.7 Clin Interv Aging
- 5.1 Drug Des Dev Ther
- 3.1 Int J Chronic Obstr
- 6.6 Int J Nanomed
- 2.6 Int J Women's Health
- 2.9 Neuropsych Dis Treat
- 2.8 OncoTargets Ther
- 2.0 Patient Prefer Adher
- 2.2 Ther Clin Risk Manag
- 2.5 J Pain Res
- 3.0 Diabet Metab Synd Ob
- 3.2 Psychol Res Behav Ma
- 3.4 Nat Sci Sleep
- 1.8 Pharmgenomics Pers Med
- 2.0 Risk Manag Healthc Policy
- 4.1 J Inflamm Res
- 2.0 Int J Gen Med
- 3.4 J Hepatocell Carcinoma
- 3.0 J Asthma Allergy
- 2.2 Clin Cosmet Investig Dermatol
- 2.4 J Multidiscip Healthc
已发表论文
个性化合理药物监测结合 KABP 模型健康教育以提高 CAR-T 细胞治疗的依从性和预后
Authors Yang G, Li L, Li Y, Yuan H, Chen T, Wei T, Peng Z
Received 17 June 2025
Accepted for publication 12 November 2025
Published 18 December 2025 Volume 2025:19 Pages 4131—4140
DOI https://doi.org/10.2147/PPA.S547864
Checked for plagiarism Yes
Review by Single anonymous peer review
Peer reviewer comments 2
Editor who approved publication: Professor Qizhi (Cathy) Yao
Guimei Yang,1,* Lihong Li,2,* Yanchun Li,3 Huihua Yuan,4 Tingting Chen,1 Ting Wei,1 Zhiqiang Peng1
1Department of Lymphatic Hematologic Oncology, Jiangxi Cancer Hospital, Nanchang, Jiangxi, People’s Republic of China; 2Department of Geriatric Oncology, Jiangxi Cancer Hospital, Nanchang, Jiangxi, People’s Republic of China; 3Department of Integrated Chinese and Western Medicine, Jiangxi Cancer Hospital, Nanchang, Jiangxi, People’s Republic of China; 4Department of Abdominal Oncology, Jiangxi Cancer Hospital, Nanchang, Jiangxi, People’s Republic of China
*These authors contributed equally to this work
Correspondence: Zhiqiang Peng, Department of Lymphatic Hematologic Oncology, Jiangxi Cancer Hospital, 519 Beijing East Road, Nanchang, Jiangxi, 330029, People’s Republic of China, Email 13870892637@163.com
Purpose: Complications such as tumor lysis syndrome occur during the Chimeric antigen receptor (CAR)-T cell treatment process, which adversely affects the treatment effect. The aim of this study is to study the combination of personalised rational medication monitoring and the Knowledge, Attitude, and Behavior (KABP) model health education to improve the adherence and prognosis of CAR-T cell therapy.
Patients and Methods: 91 patients with lymphoma and multiple myeloma who received CAR-T cell therapy in our hospital from January 2021 to December 2024 were included in this single-retrospective study and divided into the control group (n=46, routine care) and the observation group (n=45, routine care + personalised rational medication monitoring combined with KABP model health education) based on the treatment methods. Compliance, clinical treatment efficacy, self-care ability, Functional Assessment of Cancer Therapy-General (FACT-G) scale, State-Trait Anxiety Inventory (STAI), and Knowledge, Attitude, and Behavior (KAB) scale were compared between the two groups.
Results: The observation group demonstrated significantly higher total compliance and clinical efficacy compared to the control group (P < 0.05). Following personalized rational drug monitoring and KABP model health education post-management, the observation group also exhibited higher scores in self-care ability, FACT-G, and KAB, along with lower STAI scores than the control group (P < 0.05).
Conclusion: This approach proves beneficial in enhancing patient adherence, treatment effectiveness, and quality of life in CAR-T cell therapy.
Keywords: chimeric antigen receptor T cells, KABP model health education, personalised rational medication monitoring, adherence
1Department of Lymphatic Hematologic Oncology, Jiangxi Cancer Hospital, Nanchang, Jiangxi, People’s Republic of China; 2Department of Geriatric Oncology, Jiangxi Cancer Hospital, Nanchang, Jiangxi, People’s Republic of China; 3Department of Integrated Chinese and Western Medicine, Jiangxi Cancer Hospital, Nanchang, Jiangxi, People’s Republic of China; 4Department of Abdominal Oncology, Jiangxi Cancer Hospital, Nanchang, Jiangxi, People’s Republic of China
*These authors contributed equally to this work
Correspondence: Zhiqiang Peng, Department of Lymphatic Hematologic Oncology, Jiangxi Cancer Hospital, 519 Beijing East Road, Nanchang, Jiangxi, 330029, People’s Republic of China, Email 13870892637@163.com
Purpose: Complications such as tumor lysis syndrome occur during the Chimeric antigen receptor (CAR)-T cell treatment process, which adversely affects the treatment effect. The aim of this study is to study the combination of personalised rational medication monitoring and the Knowledge, Attitude, and Behavior (KABP) model health education to improve the adherence and prognosis of CAR-T cell therapy.
Patients and Methods: 91 patients with lymphoma and multiple myeloma who received CAR-T cell therapy in our hospital from January 2021 to December 2024 were included in this single-retrospective study and divided into the control group (n=46, routine care) and the observation group (n=45, routine care + personalised rational medication monitoring combined with KABP model health education) based on the treatment methods. Compliance, clinical treatment efficacy, self-care ability, Functional Assessment of Cancer Therapy-General (FACT-G) scale, State-Trait Anxiety Inventory (STAI), and Knowledge, Attitude, and Behavior (KAB) scale were compared between the two groups.
Results: The observation group demonstrated significantly higher total compliance and clinical efficacy compared to the control group (P < 0.05). Following personalized rational drug monitoring and KABP model health education post-management, the observation group also exhibited higher scores in self-care ability, FACT-G, and KAB, along with lower STAI scores than the control group (P < 0.05).
Conclusion: This approach proves beneficial in enhancing patient adherence, treatment effectiveness, and quality of life in CAR-T cell therapy.
Keywords: chimeric antigen receptor T cells, KABP model health education, personalised rational medication monitoring, adherence